UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  December 22, 2008

 

Momenta Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

(617) 491-9700

(Registrant’s telephone number,
including area code)

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01                                           Other Events

 

As previously disclosed, in June 2007, Momenta Pharmaceuticals, Inc. (the “Company”) and Sandoz AG (“Sandoz”) signed a Collaboration and License Agreement (the “2006 Collaboration”) to exclusively collaborate on the development and commercialization of four product candidates.  Under the terms of the 2006 Collaboration, the Company and Sandoz agreed to (i) jointly develop, manufacture and commercialize M356, a generic version of Copaxone (glatiramer acetate), worldwide; (ii) expand the geographic markets related to M-Enoxaparin to include the European Union; and (iii) exclusively collaborate on the development and commercialization of two biosimilar products, referred to as M178 and M249.

 

On December 22, the Company and Sandoz agreed to terminate their collaborative program with regard to M249, primarily due to the commercial prospects for M249, including taking into consideration the number of marketed products that would be competing with M249 at the expected time of launch.  Of the $188.0 million in milestone payments that the Company was eligible to receive under the 2006 Collaboration (if all milestones were achieved for the four product candidates), the milestone payments related to M249 totaled $10.0 million.  The Company is continuing to collaborate with Sandoz on M356, M-Enoxaparin and M178.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

	MOMENTA PHARMACEUTICALS, INC.
	By:
		/s/ Richard P. Shea
		Richard P. Shea
		Chief Financial Officer
		(Principal Financial Officer)
Date: December 23, 2008

 

3